Modulation of Cellular Migration and Survival by c-Myc through the Downregulation of Urokinase (uPA) and uPA Receptor

REFERENCES

• Alfano, D., I. Iaccarino, and M. P. Stoppelli. 2006. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J. Biol. Chem. 281:17758–17767.
   PubMedGoogle Scholar
• Andreasen, P. A., L. Kjøller, L. Christensen, and M. J. Duffy. 1997. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72:1–22.
   PubMed Web of Science ®Google Scholar
• Bild, A. H., G. Yao, J. T. Chang, Q. Wang, A. Potti, D. Chasse, M.-B. Joshi, D. Harpole, J. M. Lancaster, A. Berchuck, J. A. Olson, J. R. Marks, H. K. Dressman, M. West, and J. R. Nevins. 2006. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353–357.
   PubMed Web of Science ®Google Scholar
• Blasi, F., and P. Carmeliet. 2002. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3:932–943.
   PubMed Web of Science ®Google Scholar
• Brenner, C., R. Deplus, C. Didelot, A. Loriot, E. Viré, C. De Smet, A. Gutierrez, D. Danovi, D. Bernard, T. Boon, P. G. Pelicci, B. Amati, T. Kouzarides, Y. de Launoit, L. Di Croce, and F. Fuks. 2005. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J. 24:336–346.
   PubMed Web of Science ®Google Scholar
• Cappellen, D., T. Schlange, M. Bauer, F. Maurer, and N. E. Hynes. 2007. Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep. 8:70–76.
   PubMedGoogle Scholar
• Carriero, M. V., S. Del Vecchio, M. Capozzoli, P. Franco, L. Fontana, A. Zannetti, G. Botti, G. D'Aiuto, M. Salvatore, and M. P. Stoppelli. 1999. Urokinase receptor interacts with αvβ5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 59:5307–5314.
   PubMedGoogle Scholar
• Carriero, M. V., P. Franco, S. Del Vecchio, O. Massa, G. Botti, G. D'Aiuto, M. P. Stoppelli, and M. Salvatore. 1994. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res. 54:5445–5454.
   PubMedGoogle Scholar
• Chapman, H. A. 1997. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9:714–724.
   PubMed Web of Science ®Google Scholar
• Claassen, G. F., and S. R. Hann. 1999. Myc-mediated transformation: the repression connection. Oncogene 18:2925–2933.
   PubMedGoogle Scholar
• Dang, C. V., K. A. O'Donnell, K. I. Zeller, T. Nguyen, R. C. Osthus, and F. Li. 2006. The c-Myc target gene network. Semin. Cancer Biol. 16:253–264.
   PubMed Web of Science ®Google Scholar
• Drayton, S., J. Rowe, R. Jones, R. Vatcheva, D. Cuthbert-Heavens, J. Marshall, M. Fried, and G. Peters. 2003. Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell 4:301–310.
   PubMed Web of Science ®Google Scholar
• Eilers, M., and R. N. Eisenman. 2008. Myc's broad reach. Genes Dev. 22:2755–2766.
   PubMed Web of Science ®Google Scholar
• Evan, G., and T. Littlewood. 1998. A matter of life and cell death. Science 281:1317–1322.
   PubMed Web of Science ®Google Scholar
• Evan, G. I., A. H. Wyllie, C. S. Gilbert, T. D. Littlewood, H. Land, M. Brooks, C. M. Waters, L. Z. Penn, and D. C. Hancock. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119–128.
   PubMed Web of Science ®Google Scholar
• Fanidi, A., E. A. Harrington, and G. I. Evan. 1992. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554–556.
   PubMed Web of Science ®Google Scholar
• Farmer, P., H. Bonnefoi, P. Anderle, D. Cameron, P. Wirapati, P. Wirapati, V. Becette, S. André, M. Piccart, M. Campone, E. Brain, G. Macgrogan, T. Petit, J. Jassem, F. Bibeau, E. Blot, J. Bogaerts, M. Aguet, J. Bergh, R. Iggo, and M. Delorenzi. 2009. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15:68–74.
   PubMed Web of Science ®Google Scholar
• Frye, M., C. Gardner, E. R. Li, I. Arnold, and F. M. Watt. 2003. Evidence that Myc activation depletes the epidermal stem cell compartment by modulating adhesive interactions with the local microenvironment. Development 130:2793–2808.
   PubMed Web of Science ®Google Scholar
• Gartel, A. L., X. Ye, E. Goufman, P. Shianov, N. Hay, F. Najmabadi, and A. L. Tyner. 2001. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. U. S. A. 98:4510–4515.
   PubMed Web of Science ®Google Scholar
• Grandori, C., S. M. Cowley, L. P. James, and R. N. Eisenman. 2000. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16:653–699.
   PubMed Web of Science ®Google Scholar
• Harbeck, N., R. E. Kates, M. P. Look, M. E. Meijer-Van Gelder, J. G. M. Klijn, A. Krüger, M. Kiechle, F. Jänicke, M. Schmitt, and J. A. Foekens. 2002. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 62:4617–4622.
   PubMed Web of Science ®Google Scholar
• Harrington, E. A., M. R. Bennett, A. Fanidi, and G. I. Evan. 1994. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13:3286–3295.
   PubMed Web of Science ®Google Scholar
• Holst-Hansen, C., B. Johannessen, G. Høyer-Hansen, J. Rømer, V. Ellis, and N. Brünner. 1996. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin. Exp. Metastasis 14:297–307.
   PubMed Web of Science ®Google Scholar
• Iaccarino, I., D. Hancock, G. Evan, and J. Downward. 2003. c-Myc induces cytochrome c release in Rat1 fibroblasts by increasing outer mitochondrial membrane permeability in a Bid-dependent manner. Cell Death Differ. 10:599–608.
   PubMedGoogle Scholar
• Juin, P., A. O. Hueber, T. Littlewood, and G. Evan. 1999. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 13:1367–1381.
   PubMed Web of Science ®Google Scholar
• Kauffmann-Zeh, A., P. Rodriguez-Viciana, E. Ulrich, C. Gilbert, P. Coffer, J. Downward, and G. Evan. 1997. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385:544–548.
   PubMed Web of Science ®Google Scholar
• Land, H., L. F. Parada, and R. A. Weinberg. 1983. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596–602.
   PubMed Web of Science ®Google Scholar
• Lengyel, E., E. Stepp, R. Gum, and D. Boyd. 1995. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J. Biol. Chem. 270:23007–23012.
   PubMedGoogle Scholar
• Littlewood, T. D., D. C. Hancock, P. S. Danielian, M. G. Parker, and G. I. Evan. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23:1686–1690.
   PubMed Web of Science ®Google Scholar
• Lowe, S. W., E. Cepero, and G. Evan. 2004. Intrinsic tumour suppression. Nature 432:307–315.
   PubMed Web of Science ®Google Scholar
• Muller, S. M., E. Okan, and P. Jones. 2000. Regulation of urokinase receptor transcription by Ras- and Rho-family GTPases. Biochem. Biophys. Res. Commun. 270:892–898.
   PubMed Web of Science ®Google Scholar
• O'Connell, B. C., A. F. Cheung, C. P. Simkevich, W. Tam, X. Ren, M. K. Mateyak, and J. M. Sedivy. 2003. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J. Biol. Chem. 278:12563–12573.
   PubMed Web of Science ®Google Scholar
• Oster, S. K., C. S. W. Ho, E. L. Soucie, and L. Z. Penn. 2002. The myc oncogene: MarvelouslY Complex. Adv. Cancer Res. 84:81–154.
   PubMed Web of Science ®Google Scholar
• Patel, J. H., and S. B. McMahon. 2006. Targeting of Miz-1 is essential for Myc-mediated apoptosis. J. Biol. Chem. 281:3283–3289.
   PubMedGoogle Scholar
• Pelengaris, S., M. Khan, and G. I. Evan. 2002. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109:321–334.
   PubMed Web of Science ®Google Scholar
• Peukert, K., P. Staller, A. Schneider, G. Carmichael, F. Hänel, and M. Eilers. 1997. An alternative pathway for gene regulation by Myc. EMBO J. 16:5672–5686.
   PubMed Web of Science ®Google Scholar
• Preissner, K. T., S. M. Kanse, and A. E. May. 2000. Urokinase receptor: a molecular organizer in cellular communication. Curr. Opin. Cell Biol. 12:621–628.
   PubMedGoogle Scholar
• Resnati, M., I. Pallavicini, J. M. Wang, J. Oppenheim, C. N. Serhan, M. Romano, and F. Blasi. 2002. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. U. S. A. 99:1359–1364.
   PubMed Web of Science ®Google Scholar
• Song, L., T. Ara, H.-W. Wu, C.-W. Woo, C. P. Reynolds, R. C. Seeger, Y. A. DeClerck, C. J. Thiele, R. Sposto, and L. S. Metelitsa. 2007. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J. Clin. Invest. 117:2702–2712.
   PubMed Web of Science ®Google Scholar
• Stoppelli, M. P., A. Corti, A. Soffientini, G. Cassani, F. Blasi, and R. K. Assoian. 1985. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. U. S. A. 82:4939–4943.
   PubMedGoogle Scholar
• Stoppelli, M. P., C. Tacchetti, M. V. Cubellis, A. Corti, V. J. Hearing, G. Cassani, E. Appella, and F. Blasi. 1986. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 45:675–684.
   PubMed Web of Science ®Google Scholar
• Strasser, A., A. W. Harris, M. L. Bath, and S. Cory. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331–333.
   PubMed Web of Science ®Google Scholar
• Vassalli, J. D., D. Baccino, and D. Belin. 1985. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100:86–92.
   PubMed Web of Science ®Google Scholar
• Vocca, I., P. Franco, D. Alfano, G. Votta, M. V. Carriero, Y. Estrada, M. Caputi, P. A. Netti, L. Ossowski, and M. P. Stoppelli. 2009. Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of αvβ5 integrin activation. Int. J. Cancer 124:316–325.
   PubMed Web of Science ®Google Scholar
• Waikel, R. L., Y. Kawachi, P. A. Waikel, X. J. Wang, and D. R. Roop. 2001. Deregulated expression of c-Myc depletes epidermal stem cells. Nat. Genet. 28:165–168.
   PubMed Web of Science ®Google Scholar
• Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424–2433.
   PubMed Web of Science ®Google Scholar